Chemed (NYSE:CHE) Research Coverage Started at started coverage on shares of Chemed (NYSE:CHEGet Rating) in a research report sent to investors on Thursday morning. The brokerage issued a buy rating on the stock.

Separately, Royal Bank of Canada upped their price target on shares of Chemed from $545.00 to $587.00 and gave the company an outperform rating in a report on Monday, February 27th.

Chemed Trading Down 0.8 %

CHE opened at $514.70 on Thursday. The stock has a market capitalization of $7.69 billion, a PE ratio of 31.14, a P/E/G ratio of 2.81 and a beta of 0.52. The firm’s fifty day moving average price is $507.07 and its 200 day moving average price is $491.67. The company has a debt-to-equity ratio of 0.12, a current ratio of 0.92 and a quick ratio of 0.88. Chemed has a 12-month low of $430.16 and a 12-month high of $539.13.

Chemed (NYSE:CHEGet Rating) last posted its quarterly earnings results on Friday, February 24th. The company reported $5.39 earnings per share (EPS) for the quarter, beating the consensus estimate of $5.30 by $0.09. The firm had revenue of $546.65 million for the quarter, compared to analysts’ expectations of $546.60 million. Chemed had a net margin of 11.69% and a return on equity of 41.54%. The firm’s quarterly revenue was up 1.0% on a year-over-year basis. During the same period in the prior year, the company posted $5.25 earnings per share. As a group, research analysts expect that Chemed will post 20.85 EPS for the current fiscal year.

Chemed Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Friday, March 17th. Shareholders of record on Monday, February 27th were issued a dividend of $0.38 per share. The ex-dividend date of this dividend was Friday, February 24th. This represents a $1.52 dividend on an annualized basis and a dividend yield of 0.30%. Chemed’s dividend payout ratio (DPR) is 9.20%.

Insiders Place Their Bets

In other Chemed news, CEO Kevin J. Mcnamara sold 2,000 shares of the stock in a transaction on Thursday, March 9th. The shares were sold at an average price of $507.32, for a total transaction of $1,014,640.00. Following the sale, the chief executive officer now directly owns 121,613 shares of the company’s stock, valued at $61,696,707.16. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 4.03% of the stock is owned by corporate insiders.

Institutional Trading of Chemed

Institutional investors and hedge funds have recently modified their holdings of the business. U.S. Capital Wealth Advisors LLC acquired a new stake in shares of Chemed during the fourth quarter worth $26,000. Dark Forest Capital Management LP acquired a new stake in shares of Chemed during the second quarter worth $34,000. IFP Advisors Inc raised its holdings in shares of Chemed by 13.7% during the third quarter. IFP Advisors Inc now owns 274 shares of the company’s stock worth $37,000 after purchasing an additional 33 shares during the period. Canada Pension Plan Investment Board acquired a new stake in shares of Chemed during the first quarter worth $46,000. Finally, Quadrant Capital Group LLC grew its position in shares of Chemed by 29.2% during the third quarter. Quadrant Capital Group LLC now owns 115 shares of the company’s stock worth $50,000 after acquiring an additional 26 shares during the last quarter. 91.12% of the stock is owned by institutional investors and hedge funds.

About Chemed

(Get Rating)

Chemed Corp. engages in the provision of healthcare and maintenance services. It operates through the VITAS and Roto-Rooter segments. The VITAS segment offers hospice and palliative care services to patients through a network of physicians, registered nurses, home health aides, social workers, clergy, and volunteers.

Recommended Stories

Receive News & Ratings for Chemed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chemed and related companies with's FREE daily email newsletter.